Gilead and Teva Reach Settlement Agreement in Viread® Patent Litigation
FOSTER CITY, Calif. -- February 19, 2013
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Gilead and Teva
Pharmaceuticals have reached an agreement in principle to settle the ongoing
patent litigation concerning the patents protecting Viread® (tenofovir
disoproxil fumarate), a treatment for HIV infection and chronic hepatitis B.
Under the terms of the settlement, Teva will be allowed to launch a generic
version of Viread on December 15, 2017.
“We believe strongly in the validity of our intellectual property,” said John
Milligan, PhD, Gilead’s President and Chief Operating Officer. “This
settlement, however, removes some uncertainty and minimizes further
distraction and investment of human and financial resources associated with
The trial in this litigation, which was scheduled to begin on Wednesday,
February 20 in the District Court for the Southern District of New York, has
been adjourned pending completion of activities necessary to finalize the
About Gilead Sciences
Gilead Sciences is a biopharmaceutical company that discovers, develops and
commercializes innovative therapeutics in areas of unmet medical need. The
company’s mission is to advance the care of patients suffering from
life-threatening diseases worldwide. Headquartered in Foster City, California,
Gilead has operations in North America, Europe and Asia Pacific.
For more information on Gilead Sciences, please visit the company’s website at
www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead
Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.
Gilead Sciences, Inc.
Patrick O’Brien, 650-522-1936 (Investors)
Amy Flood, 650-522-5643 (Media)
Press spacebar to pause and continue. Press esc to stop.